185 related articles for article (PubMed ID: 26584137)
1. Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies.
Wallukat G; Müller J; Haberland A; Berg S; Schulz A; Freyse EJ; Vetter R; Salzsieder E; Kreutz R; Schimke I
Atherosclerosis; 2016 Jan; 244():44-7. PubMed ID: 26584137
[TBL] [Abstract][Full Text] [Related]
2. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies.
Haberland A; Wallukat G; Dahmen C; Kage A; Schimke I
Circ Res; 2011 Oct; 109(9):986-92. PubMed ID: 21868696
[TBL] [Abstract][Full Text] [Related]
3. The first aptamer-apheresis column specifically for clearing blood of β1-receptor autoantibodies.
Wallukat G; Haberland A; Berg S; Schulz A; Freyse EJ; Dahmen C; Kage A; Dandel M; Vetter R; Salzsieder E; Kreutz R; Schimke I
Circ J; 2012; 76(10):2449-55. PubMed ID: 22850243
[TBL] [Abstract][Full Text] [Related]
4. Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment.
Haberland A; Wallukat G; Schimke I
Trends Cardiovasc Med; 2011 Aug; 21(6):177-82. PubMed ID: 22814426
[TBL] [Abstract][Full Text] [Related]
5. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.
Wallukat G; Schimke I
Semin Immunopathol; 2014 May; 36(3):351-63. PubMed ID: 24777744
[TBL] [Abstract][Full Text] [Related]
6. Functional autoantibody diseases: Basics and treatment related to cardiomyopathies.
Becker NP; Goettel P; Mueller J; Wallukat G; Schimke I
Front Biosci (Landmark Ed); 2019 Jan; 24(1):48-95. PubMed ID: 30468647
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies Directed Against the Endothelin A Receptor in Patients With Benign Prostatic Hyperplasia.
Wallukat G; Jandrig B; Kunze R; Wendler JJ; Müller J; Schostak M; Schimke I
Prostate; 2017 Apr; 77(5):458-465. PubMed ID: 27882567
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyopathy - An approach to the autoimmune background.
Becker NP; Müller J; Göttel P; Wallukat G; Schimke I
Autoimmun Rev; 2017 Mar; 16(3):269-286. PubMed ID: 28163240
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats.
Haberland A; Wallukat G; Berg S; Schulz AM; Freyse EJ; Vetter R; Salzsieder E; Müller J; Kreutz R; Schimke I
Mol Cell Biochem; 2014 Aug; 393(1-2):177-80. PubMed ID: 24744110
[TBL] [Abstract][Full Text] [Related]
10. Functional autoantibodies in patients with different forms of dementia.
Wallukat G; Prüss H; Müller J; Schimke I
PLoS One; 2018; 13(3):e0192778. PubMed ID: 29538413
[TBL] [Abstract][Full Text] [Related]
11. Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors.
Haberland A; Holtzhauer M; Schlichtiger A; Bartel S; Schimke I; Müller J; Dandel M; Luppa PB; Wallukat G
Eur J Pharmacol; 2016 Oct; 789():37-45. PubMed ID: 27375076
[TBL] [Abstract][Full Text] [Related]
12. The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes.
Werner S; Wallukat G; Becker NP; Wenzel K; Müller J; Schimke I; Wess G
ESC Heart Fail; 2020 Jun; 7(3):844-855. PubMed ID: 32212256
[TBL] [Abstract][Full Text] [Related]
13. Analytics of Functional Autoantibodies in Patients with Chagas Disease.
Wallukat G; Wenzel K; Schimke I
Methods Mol Biol; 2019; 1955():247-261. PubMed ID: 30868533
[TBL] [Abstract][Full Text] [Related]
14. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients.
Wallukat G; Muñoz Saravia SG; Haberland A; Bartel S; Araujo R; Valda G; Duchen D; Diaz Ramirez I; Borges AC; Schimke I
J Am Coll Cardiol; 2010 Feb; 55(5):463-8. PubMed ID: 20117461
[TBL] [Abstract][Full Text] [Related]
15. The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors.
Haberland A; Wallukat G; Schimke I
Pharm Pat Anal; 2013 Mar; 2(2):231-48. PubMed ID: 24237028
[TBL] [Abstract][Full Text] [Related]
16. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension.
Dandel M; Wallukat G; Englert A; Hetzer R
Atheroscler Suppl; 2013 Jan; 14(1):203-11. PubMed ID: 23357166
[TBL] [Abstract][Full Text] [Related]
17. Role of β₁-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy.
Dandel M; Wallukat G; Potapov E; Hetzer R
Immunobiology; 2012 May; 217(5):511-20. PubMed ID: 21820755
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies directed against α1-adrenergic receptor and endothelin receptor A in patients with prostate cancer.
Wallukat G; Jandrig B; Becker NP; Wendler JJ; Göttel P; Müller J; Schostak M; Schimke I
Auto Immun Highlights; 2020 Sep; 11(1):13. PubMed ID: 32977857
[TBL] [Abstract][Full Text] [Related]
19. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus.
Dandel M; Englert A; Wallukat G; Riese A; Knosalla C; Stein J; Hetzer R
Atheroscler Suppl; 2015 May; 18():124-33. PubMed ID: 25936316
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy.
Dandel M; Wallukat G; Englert A; Lehmkuhl HB; Knosalla C; Hetzer R
Eur J Heart Fail; 2012 Dec; 14(12):1374-88. PubMed ID: 22892122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
